"New treatments (pharmacological and device based) are currently in development to expand our OAB armamentarium," write Nathan Chertack, MD, and Gary Lemack, MD.
Nathan Chertack, MD
Advertisement
Articles by Nathan Chertack, MD
Advertisement
Latest Updated Articles
New developments may change treatment of OABApril 21st 2020
Advertisement
Advertisement
Trending on Urology Times
1
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
2
FDA approves durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC
3
Survey: Service members and veterans with NMIBC report barriers to treatment access
4
Q&A: Where ProACT fits in the male stress urinary incontinence algorithm
5